PL2746404T3 - Środek przeciwnowotworowy i sposób przewidywania efektu terapeutycznego u pacjentów z rakiem jelita grubego z mutacją kras - Google Patents

Środek przeciwnowotworowy i sposób przewidywania efektu terapeutycznego u pacjentów z rakiem jelita grubego z mutacją kras

Info

Publication number
PL2746404T3
PL2746404T3 PL12824342T PL12824342T PL2746404T3 PL 2746404 T3 PL2746404 T3 PL 2746404T3 PL 12824342 T PL12824342 T PL 12824342T PL 12824342 T PL12824342 T PL 12824342T PL 2746404 T3 PL2746404 T3 PL 2746404T3
Authority
PL
Poland
Prior art keywords
kras
patients
therapeutic effect
colorectal cancer
prediction method
Prior art date
Application number
PL12824342T
Other languages
English (en)
Inventor
Masanobu Ito
Hiroyuki Okabe
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of PL2746404T3 publication Critical patent/PL2746404T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
PL12824342T 2011-08-16 2012-08-15 Środek przeciwnowotworowy i sposób przewidywania efektu terapeutycznego u pacjentów z rakiem jelita grubego z mutacją kras PL2746404T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011177838 2011-08-16
PCT/JP2012/070745 WO2013024865A1 (ja) 2011-08-16 2012-08-15 Kras遺伝子変異型の結腸直腸癌患者に対する抗腫瘍剤及び治療効果予測方法
EP12824342.5A EP2746404B1 (en) 2011-08-16 2012-08-15 Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer

Publications (1)

Publication Number Publication Date
PL2746404T3 true PL2746404T3 (pl) 2018-04-30

Family

ID=47715182

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12824342T PL2746404T3 (pl) 2011-08-16 2012-08-15 Środek przeciwnowotworowy i sposób przewidywania efektu terapeutycznego u pacjentów z rakiem jelita grubego z mutacją kras

Country Status (21)

Country Link
US (1) US9371380B2 (pl)
EP (1) EP2746404B1 (pl)
JP (1) JP5832541B2 (pl)
KR (1) KR101693090B1 (pl)
CN (1) CN103764847B (pl)
AU (1) AU2012295841B2 (pl)
CY (1) CY1119869T1 (pl)
DK (1) DK2746404T3 (pl)
ES (1) ES2659264T3 (pl)
HR (1) HRP20180130T1 (pl)
HU (1) HUE035347T2 (pl)
LT (1) LT2746404T (pl)
NO (1) NO2746404T3 (pl)
PL (1) PL2746404T3 (pl)
PT (1) PT2746404T (pl)
RS (1) RS56911B1 (pl)
RU (1) RU2585528C2 (pl)
SI (1) SI2746404T1 (pl)
SM (1) SMT201800108T1 (pl)
TW (1) TWI550089B (pl)
WO (1) WO2013024865A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160082032A1 (en) * 2013-05-17 2016-03-24 Taiho Pharmaceutical Co., Ltd. Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased
MA42543A (fr) 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques
CA3003090A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Cancer vaccines
UA123403C2 (uk) * 2016-02-05 2021-03-31 Тайхо Фармасьютікал Ко., Лтд. Спосіб лікування хворих на рак з тяжкою нирковою недостатністю
WO2018144082A1 (en) * 2017-02-01 2018-08-09 Modernatx, Inc. Rna cancer vaccines
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799783B2 (en) 2005-01-26 2010-09-21 Taiho Pharmaceutical Co., Ltd. Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
HUE033306T2 (hu) 2005-01-26 2017-11-28 Taiho Pharmaceutical Co Ltd Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog

Also Published As

Publication number Publication date
EP2746404A4 (en) 2015-04-08
RU2585528C2 (ru) 2016-05-27
RU2014109999A (ru) 2015-10-10
JP5832541B2 (ja) 2015-12-16
HUE035347T2 (en) 2018-05-02
CN103764847A (zh) 2014-04-30
NO2746404T3 (pl) 2018-05-05
KR20140057328A (ko) 2014-05-12
TW201319257A (zh) 2013-05-16
CN103764847B (zh) 2016-05-11
KR101693090B1 (ko) 2017-01-04
SMT201800108T1 (it) 2018-05-02
EP2746404B1 (en) 2017-12-06
WO2013024865A1 (ja) 2013-02-21
EP2746404A1 (en) 2014-06-25
TWI550089B (zh) 2016-09-21
ES2659264T3 (es) 2018-03-14
SI2746404T1 (en) 2018-04-30
HRP20180130T1 (hr) 2018-04-06
RS56911B1 (sr) 2018-05-31
DK2746404T3 (en) 2018-01-15
US9371380B2 (en) 2016-06-21
US20140213602A1 (en) 2014-07-31
CY1119869T1 (el) 2018-06-27
JPWO2013024865A1 (ja) 2015-03-05
LT2746404T (lt) 2018-04-25
PT2746404T (pt) 2018-01-10
AU2012295841A1 (en) 2014-04-03
AU2012295841B2 (en) 2015-12-10
HK1197086A1 (zh) 2015-01-02

Similar Documents

Publication Publication Date Title
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
IL238945A0 (en) System and method for optogenetic therapy
EP2788075A4 (en) DEVICE AND METHOD FOR REDUCING THE TRANSTHORACOID IMPEDANCE OF A PATIENT
PL2542585T3 (pl) Sposoby leczenia nowotworu jelita grubego
IL232530A0 (en) Combined cancer treatment
IL230698A0 (en) Use of preparations containing crizotinib to treat cancer
IL228430A0 (en) Cancer treatment
PL2780332T3 (pl) Morfolinylobenzotriazyny do zastosowania w terapii rakowej
SG10201601301RA (en) Methods for predicting and improving the survival of gastric cancer patients
IL232493A0 (en) A method for quantifying cancer treatment
PL2746404T3 (pl) Środek przeciwnowotworowy i sposób przewidywania efektu terapeutycznego u pacjentów z rakiem jelita grubego z mutacją kras
SG11201400976WA (en) Methods and pharmaceutical compositions for treating cancer
GB201223025D0 (en) Prediction of the treatment response to an anti-EGFR molecule in colorectal cancer patients
IL275636A (en) Medical combination for cancer treatment
GB201402983D0 (en) Compositions and methods for treatment of metastatic cancer
IL230479A0 (en) A method of treating cancer through the combined use of drugs
GB201106630D0 (en) Cancer therapy
IL237229A0 (en) Methods of treating cancer using lipoplatin
GB201113140D0 (en) Prediction and treatment of cancer
SG11201509367RA (en) Methods for predicting and improving the survival of colorectal cancer patients
ZA201208905B (en) Cancer therapy method
SG10201601715YA (en) Novel Pharmaceutical Combinations And Methods For Treating Cancer
GB201118220D0 (en) Cancer therapy
IL232266A0 (en) Cancer treatment methods
GB201121791D0 (en) Combination treatment of cancer